A small but growing set of clinical trials suggests that GLP-1 medications may improve several core features of PMOS, the hormonal condition formerly called polycystic ovary syndrome, including irregular periods, elevated testosterone, and insulin resistance. The findings were detailed in Associated Press reporting published this weekend.
The evidence is early. The trials involve small numbers of participants, no GLP-1 drug is approved to treat the condition, and independent reviewers describe the certainty of the data as low. What is not in dispute is that prescribing is already happening off-label, and that insurance denials are now a practical barrier standing between many patients and a medication their doctor has recommended.
